like
merslik
virus
futur
given
divers
cov
strain
zoonot
reservoir
penchant
emerg
broadli
activ
antivir
clearli
need
rapid
respons
new
cov
outbreak
human
domest
anim
current
approv
therapi
specif
human
cov
nhc
oral
bioavail
ribonucleosid
analog
broadspectrum
antivir
activ
variou
unrel
rna
virus
includ
influenza
ebola
cov
venezuelan
equin
enceph
viru
veev
veev
mechan
action
moa
nhc
shown
lethal
mutagenesi
deleteri
transit
mutat
accumul
viral
rna
thu
sought
determin
nhc
breadth
antivir
activ
multipl
emerg
cov
mechan
action
cov
efficaci
mous
model
cov
pathogenesi
determin
whether
nhc
block
replic
highli
pathogen
human
cov
perform
antivir
assay
cell
line
merscov
newli
emerg
first
assess
antivir
activ
nhc
merscov
human
lung
epitheli
cell
line
cell
use
recombin
merscov
express
nanoluciferas
mersnluc
measur
viru
replic
cultur
expos
dose
rang
drug
nhc
potent
antivir
averag
halfmaximum
effect
concentr
observ
cytox
similarli
treat
uninfect
cultur
across
dose
rang
cytotox
concentr
fig
therapeut
index
nhc
use
clinic
isol
perform
antivir
assay
african
green
monkey
kidney
vero
cell
found
nhc
potent
antivir
fig
determin
antivir
activ
nhc
cell
measur
infecti
viru
product
viral
genom
observ
dosedepend
reduct
viru
titer
fig
viral
genom
rna
quantit
clarifi
supernat
qrtpcr
fig
like
effect
infecti
titer
found
dosedepend
reduct
viral
genom
rna
similar
calcul
collect
data
demonstr
nhc
potent
antivir
two
genet
distinct
emerg
cov
determin
nhc
would
similarli
antivir
primari
human
cell
perform
seri
studi
primari
airway
epitheli
hae
cell
cultur
hae
model
architectur
cellular
complex
conduct
airway
readili
infect
multipl
human
zoonot
cov
includ
sarsand
merscov
first
assess
cytotox
nhc
hae
treat
extend
dose
rang
use
quantit
pcr
cell
deathrel
gene
transcript
metric
nhc
treatment
appreci
alter
gene
express
even
dose
fig
sought
determin
nhc
would
inhibit
clinic
isol
replic
hae
observ
dose
depend
reduct
infecti
viru
product
fig
merscov
infect
hae
nhc
substanti
reduc
viru
product
maxim
titer
reduct
log
averag
correl
reduc
genom
subgenom
orfn
rna
pair
sampl
fig
observ
similar
trend
titer
reduct
log
averag
copi
genom
subgenom
rna
sarscovinfect
hae
fig
thu
nhc
potent
antivir
merscov
sarscov
primari
human
epitheli
cell
cultur
without
cytotox
cov
taxonom
divid
multipl
genogroup
alpha
beta
gamma
delta
humaninfect
cov
found
alpha
beta
subgroup
thu
far
fig
high
sequenc
conserv
rnadepend
rna
polymeras
rdrp
across
cov
fig
exampl
rdrp
similar
amino
acid
ident
sarscov
fig
gain
insight
structur
conserv
rdrp
across
cov
famili
model
variat
reflect
rdrp
dendrogram
fig
onto
structur
sarscov
rdrp
fig
core
rdrp
molecul
main
structur
motif
rdrp
harbor
fig
fig
highli
conserv
among
cov
includ
previous
report
cov
resist
anoth
broad
spectrum
nucleosid
analog
rdv
mediat
rdrp
residu
model
coronaviru
mous
hepat
viru
mhv
sarscov
result
shift
fig
consequ
test
whether
rdv
resist
mutat
mhv
confer
crossresist
nhc
fact
two
rdv
resist
mutat
alon
togeth
confer
increas
sensit
inhibit
nhc
fig
previou
studi
demonstr
high
genet
barrier
nhc
veev
influenza
cov
lack
crossresist
suggest
nhc
rdv
may
select
exclus
mutual
sensit
resist
pathway
explor
breadth
antivir
efficaci
zoonot
cov
perform
antivir
assay
hae
three
suggest
potenti
zoonot
emerg
human
distantli
relat
sarslik
beta
cov
recombin
batcov
modifi
receptor
bind
domain
facilit
growth
cell
cultur
lastli
batcov
merslik
beta
cov
nhc
diminish
infecti
viru
product
level
genomicsubgenom
viral
rna
hae
dosedepend
manner
three
batcov
fig
therefor
antivir
activ
nhc
limit
natur
amino
acid
variat
rdrp
among
group
group
cov
vari
almost
moreov
data
suggest
anoth
sarsor
merslik
viru
spillov
human
futur
would
like
suscept
antivir
activ
nhc
recent
shown
nhc
treatment
increas
mutat
rate
viral
genom
rna
rsv
veev
influenza
previou
studi
use
rna
seq
show
overal
transit
mutat
frequenc
increas
nhc
treatment
mhv
merscov
infect
continu
cell
line
sought
determin
nhc
would
increas
mutat
frequenc
merscov
infect
human
primari
hae
use
merscovinfect
hae
treat
either
vehicl
dose
rang
nhc
rdv
show
drug
reduc
viru
titer
dosedepend
manner
fig
use
highlysensit
highfidel
deep
sequenc
approach
primer
id
ng
use
barcod
degener
primer
illumina
index
librari
determin
accur
mutat
rate
viral
rna
product
use
approach
analyz
bp
region
viral
genom
rna
nonstructur
protein
error
rate
base
vehicl
rdv
treat
cultur
low
rdv
report
act
via
chain
termin
nascent
viral
rna
thu
low
error
rate
rdvtreat
cultur
line
propos
moa
contrast
error
rate
significantli
increas
nhctreat
merscov
rna
dosedepend
manner
twoway
anova
dunnett
multipl
comparison
test
increas
p
hpi
increas
p
hpi
p
hpi
fig
examin
mutat
spectra
induc
nhc
incorpor
viral
rna
substitut
either
cytosin
c
uracil
u
rnamutagen
antivir
may
incorpor
nascent
neg
posit
sens
rna
genom
replic
fig
adeninetoguanin
atog
uraciltocytosin
utoc
transit
enrich
merscov
genom
rna
nhc
dosedepend
manner
fig
collect
data
use
highfidel
sequenc
analysi
demonstr
specif
enrich
g
c
u
transit
merscov
rna
nhc
treatment
primari
hae
cell
cultur
given
promis
antivir
activ
nhc
vitro
next
evalu
vivo
efficaci
use
oral
bioavail
prodrug
nhc
ester
design
improv
vivo
pharmacokinet
oral
bioavail
human
nonhuman
primat
importantli
plasma
profil
nhc
similar
mice
follow
oral
deliveri
first
perform
prophylact
dose
escal
studi
mice
oral
administ
vehicl
peg
cremophor
water
mgkg
prior
intranas
infect
pfu
mouseadapt
sarscov
vehicl
drug
everi
hour
thereaft
begin
day
postinfect
dpi
end
studi
bodi
weight
loss
compar
vehicl
treatment
significantli
diminish
mgkg
prevent
mgkg
prophylaxi
twoway
anova
dunnett
multipl
comparison
test
p
fig
lung
hemorrhag
also
significantli
reduc
dpi
mgkg
treatment
kruskalw
test
p
fig
interestingli
dosedepend
reduct
sarscov
lung
titer
median
titer
mgkg
pfuml
mgkg
pfuml
mgkg
pfuml
vehicl
pfuml
signific
differ
kruskalw
dunn
multipl
comparison
test
among
vehicl
mgkg
p
mgkg
p
group
thu
prophylact
oral
administ
robustli
antivir
abl
prevent
sarscov
replic
diseas
sinc
mgkg
group
significantli
diminish
weight
loss
hemorrhag
reduc
lung
titer
near
undetect
level
test
dose
therapeut
treatment
condit
determin
could
improv
outcom
ongo
cov
infect
control
initi
oral
vehicl
hour
prior
infect
pfu
therapeut
condit
initi
treatment
hour
infect
initi
treatment
dose
group
perform
everi
hour
durat
studi
prophylact
treatment
initi
hour
prior
infect
therapeut
treatment
initi
hour
infect
significantli
twoway
anova
tukey
multipl
comparison
test
prevent
bodi
weight
loss
follow
sarscov
infect
dpi
thereaft
hour
p
hour
p
compar
vehicl
treat
anim
fig
treatment
initi
hpi
also
significantli
reduc
bodi
weight
loss
dpi
p
although
degre
earlier
treatment
initi
group
initi
hpi
bodi
weight
loss
differ
vehicl
dpi
p
fig
therapeut
significantli
kruskalw
dunnett
multipl
comparison
test
reduc
lung
hemorrhag
initi
hour
infect
hour
p
mirror
bodi
weight
loss
phenotyp
fig
interestingli
treat
mice
significantli
kruskalw
dunnett
multipl
comparison
test
reduc
viral
load
lung
even
hour
group
p
fig
experienc
least
protect
bodi
weight
loss
lung
hemorrhag
also
measur
pulmonari
function
via
whole
bodi
plethysmographi
wbp
fig
show
wbp
enhanc
paus
penh
metric
surrog
marker
bronchoconstrict
pulmonari
obstruct
significantli
twoway
anova
dunnett
multipl
comparison
test
improv
throughout
cours
studi
treatment
initi
hour
infect
hour
pi
dpi
p
hour
dpi
dpi
p
although
hour
group
show
sporad
improv
well
dpi
p
fig
lastli
blindli
evalu
hematoxylin
eosinstain
lung
tissu
section
histolog
featur
ali
use
two
differ
complementari
score
tool
show
treatment
initi
hour
significantli
reduc
ali
kruskalw
dunn
multipl
comparison
test
american
thorac
societi
at
lung
injuri
score
hour
p
hour
p
diffus
alveolar
damag
dad
score
hour
p
hour
p
fig
altogeth
therapeut
potent
antivir
sarscov
vivo
degre
clinic
benefit
depend
time
initi
postinfect
obtain
promis
vivo
efficaci
data
sarscov
investig
whether
would
effect
merscov
murin
ortholog
merscov
receptor
dipeptidyl
peptidas
support
viral
bind
entri
vivo
studi
perform
genet
modifi
mice
encod
murin
receptor
encod
two
human
residu
posit
mice
similar
sarscov
data
evalu
therapeut
efficaci
follow
promis
result
prophylact
studi
similar
sarscov
studi
treatment
administ
hour
intranas
mouseadapt
merscov
infect
pfu
prevent
bodi
weight
loss
dpi
twoway
anova
tukey
multipl
comparison
test
fig
p
lung
hemorrhag
dpi
kruskalw
dunn
multipl
comparison
test
p
fig
treatment
initi
hour
offer
similar
protect
unlik
bodi
weight
loss
lung
hemorrhag
data
vari
treatment
initi
time
viru
lung
titer
dpi
significantli
reduc
limit
detect
treatment
group
kruskalw
dunn
multipl
comparison
test
fig
p
interestingli
viral
genom
rna
quantifi
pair
sampl
lung
tissu
significantli
reduc
quantiti
viral
rna
oneway
anova
dunnett
multipl
comparison
test
p
initi
timedepend
manner
group
except
hour
fig
discrep
among
infecti
titer
viral
rna
suggest
accumul
mutat
render
particl
noninfecti
undetect
plaqu
assay
consist
moa
gaug
effect
treatment
lung
function
assess
pulmonari
function
wbp
mirror
bodi
weight
loss
data
normal
pulmonari
function
observ
group
treatment
initi
prior
hour
infect
twoway
anova
tukey
multipl
comparison
test
p
dpi
p
dpi
p
dpi
p
dpi
fig
collect
data
demonstr
nhc
prodrug
robustli
reduc
merscov
infecti
titer
viral
rna
pathogenesi
prophylact
earli
therapeut
condit
studi
molecular
mechan
associ
drug
perform
vivo
investig
correl
infecti
viru
product
mutagenesi
merscov
rna
therapeut
treatment
condit
use
primer
id
ng
measur
mutat
rate
viral
genom
rna
nonstructur
protein
host
interferon
stimul
gene
mrna
highli
upregul
innat
immunerel
gene
merscov
infect
fig
viral
tc
significantli
reduc
twoway
anova
tukey
multipl
comparison
test
hour
p
hour
p
hour
p
treatment
initi
timedepend
manner
fig
similar
viral
genom
rna
measur
qrtpcr
contrast
number
tc
similar
p
group
indic
neither
vehicl
drug
treatment
significantli
affect
level
mutat
mrna
transcript
fig
similar
tc
data
fig
total
error
rate
viral
significantli
increas
twoway
anova
tukey
multipl
comparison
test
group
treatment
initi
prior
hour
median
error
rate
base
p
hour
post
infect
hour
median
error
rate
base
p
hour
median
error
rate
base
p
error
rate
remain
baselin
group
fig
addit
nucleotid
transit
observ
merscov
genom
vitro
also
observ
vivo
group
treatment
initi
prior
hour
post
infect
twoway
anova
tukey
multipl
comparison
test
p
fig
importantli
transit
observ
host
mrna
fig
lastli
dosedepend
mutagenesi
viral
rna
correl
increas
codon
chang
frequenc
includ
stop
codon
mice
treatment
initi
hour
twoway
anova
tukey
multipl
comparison
test
vehicl
median
median
p
hour
median
p
fig
thu
approxim
mutat
observ
hour
hour
group
result
codon
chang
alter
protein
sequenc
extrapol
result
entireti
merscov
genom
like
caus
hour
treatment
hour
treatment
mutat
per
genom
result
amino
acid
code
chang
altogeth
data
demonstr
mutagenesi
correl
well
reduct
viral
load
strongli
suggest
error
catastrophedriven
mechan
action
therapeut
condit
past
year
three
novel
human
coronavirus
emerg
group
sarslik
cov
repres
existenti
futur
threat
global
health
evidenc
emerg
sarscov
zoonot
sarslik
bat
cov
strain
use
human
angiotensinconvert
enzym
receptor
grow
well
primari
human
airway
cell
vari
much
key
therapeut
vaccin
gene
target
thu
address
current
public
health
emerg
maxim
pandem
prepared
futur
broadbas
vaccin
therapeut
activ
higher
risk
rna
viru
famili
prone
emerg
desper
need
small
molecul
antivir
exert
antivir
effect
multipl
mechan
includ
block
viral
entri
inhibit
viral
encod
enzym
block
viru
particl
format
target
host
factor
requir
replic
multipl
direct
act
antivir
current
evalu
random
control
trial
treat
includ
hydroxychloroquin
remdesivir
lopinavirritonavir
report
broadspectrum
antivir
activ
nhc
oral
bioavail
prodrug
sarscov
merscov
current
pandem
strain
primari
human
airway
epitheli
cell
addit
cov
nhc
broadli
activ
multipl
genet
distinct
virus
includ
vee
influenza
b
ebola
chikungunya
virus
show
prophylact
therapeut
significantli
reduc
lung
viral
load
improv
pulmonari
function
mous
model
sarsand
merscov
pathogenesi
although
improv
sarsand
merscov
outcom
diminish
delay
treatment
initi
time
import
note
kinet
diseas
mice
compress
compar
human
wherea
sarsand
merscov
lung
titer
peak
dpi
mice
concurr
onset
clinic
sign
notabl
damag
lung
epithelium
human
occur
day
onset
symptom
thu
mice
window
within
treat
emerg
cov
infect
prior
peak
replic
compress
eg
hour
oseltamivir
treatment
influenza
fail
provid
protect
effect
administ
day
onset
symptom
window
treat
patient
prior
peak
viru
replic
like
first
week
symptom
pharyng
shed
highest
howev
viru
replic
shed
may
continu
sever
week
sever
patient
thu
earli
intervent
antivir
like
like
provid
clinic
benefit
although
may
opportun
sever
patient
durat
viru
replic
may
extend
current
studi
clearli
limit
lack
vivo
efficaci
test
current
robust
mous
model
recapitul
pathogenesi
observ
human
yet
exist
due
note
viru
spike
glycoprotein
mous
receptor
incompat
complic
evalu
medic
countermeasur
addit
sarscov
merscov
diseas
sever
increas
increas
age
studi
limit
lack
drug
efficaci
test
cov
age
mous
model
recapitul
agerel
increas
pathogenesi
observ
human
data
provid
manuscript
suggest
quickli
evalu
primat
model
human
diseas
use
immedi
model
merscov
sarscov
pathogenesi
newli
describ
cynomolgu
rhesu
macaqu
model
vee
influenza
exert
antivir
activ
rnadepend
rna
polymeras
lead
error
catastroph
induc
error
rate
replic
surpass
error
threshold
allow
sustain
viru
popul
process
occur
nhc
incorpor
rna
synthesi
subsequ
misread
thu
increas
mutat
rate
therefor
cov
nhc
moa
would
appear
less
like
affect
rna
proofread
activ
encod
exonucleas
function
otherwis
limit
misincorper
present
data
use
primer
id
ng
quantit
frequenc
ident
mutat
spectra
merscov
genom
drugtreat
primari
human
airway
cell
mice
singl
genom
resolut
cov
posit
sens
rna
virus
replic
neg
sens
rna
intermedi
nhc
incorpor
c
u
occur
polar
rna
found
increas
nucleotid
transit
g
g
c
u
u
c
consist
report
influenza
vee
infect
ident
condit
rdv
alter
mutat
rate
merscov
genom
rna
support
report
mechan
action
chain
termin
viral
rna
synthesi
primari
human
lung
cell
cultur
mice
infect
merscov
nhc
mutat
rate
invers
correl
reduct
infecti
viru
addit
found
posit
correl
increas
mutat
rate
frequenc
nonsynonym
mutat
degre
therapeut
efficaci
mice
explor
potenti
offtarget
effect
host
mrna
may
contribut
drug
toxic
also
examin
impact
nhc
treatment
transcript
gene
highli
induc
follow
merscov
infect
although
transcript
present
great
abund
accumul
mutat
observ
model
even
mgkg
dose
data
also
support
previou
studi
use
rnaseq
demonstr
model
coronaviru
mhv
display
increas
mutat
frequenc
follow
nhc
treatment
vitro
regard
nucleic
acid
specif
ribonucleotid
effici
remov
eukaryot
cell
dna
therefor
treat
viral
infect
mutagen
ribonucleosid
analog
show
select
incorpor
viral
genom
effici
incorpor
induc
mutat
host
cell
dna
togeth
data
strongli
support
notion
activ
nucleosid
analog
nhc
exert
antivir
effect
induct
error
catastroph
target
viru
data
suggest
merscov
proofread
activ
appear
ineffect
nhc
vitro
vivo
futur
studi
investig
antivir
activ
nhc
presenc
absenc
proofread
activ
loss
activ
increas
sensit
mhv
sarscov
replic
rdv
treatment
togeth
data
support
continu
develop
potent
broad
spectrum
antivir
could
use
treat
contemporari
newli
emerg
emerg
coronaviru
infect
futur
primari
goal
studi
determin
antivir
activ
nucleosid
analog
nhc
multipl
emerg
cov
vitro
antivir
efficaci
prodrug
mous
model
cov
pathogenesi
coupl
cell
line
primari
hae
cell
cultur
evalu
antivir
activ
nhc
three
recent
emerg
human
cov
sarscov
merscov
sarscov
merscov
data
present
hae
studi
repres
separ
human
donor
hae
singl
human
donor
evalu
drug
cytotox
hae
cell
cultur
sarscov
merscov
hae
studi
perform
biolog
triplic
hae
studi
sarsand
merslik
bat
cov
perform
two
well
per
condit
drug
effect
measur
rel
vehicl
control
vitro
comparison
vivo
perform
vehicl
control
also
aim
determin
antivir
efficaci
mous
model
cov
pathogenesi
studi
intend
provid
preclin
data
justifi
nonhuman
primat
studi
human
clinic
trial
mice
ageand
sexmatch
randomli
assign
group
infect
treatment
patholog
score
blind
boardcertifi
veterinari
pathologist
primari
data
studi
provid
data
file
efficaci
studi
perform
anim
biosafeti
level
facil
unc
chapel
hill
work
conduct
protocol
approv
institut
anim
care
use
committe
unc
chapel
hill
iacuc
protocol
accord
guidelin
set
associ
assess
accredit
laboratori
anim
care
us
depart
agricultur
parent
compound
hydroxycytidin
nhc
vitro
studi
prodrug
vivo
studi
suppli
emori
univers
institut
drug
discoveri
eidd
nhc
suppli
mm
stock
dmso
solid
solubil
vehicl
contain
cremophor
water
vv
prior
use
rdv
solubil
dmso
provid
gilead
scienc
inc
previous
describ
except
virus
use
studi
deriv
infecti
clone
isol
previous
describ
measur
cell
viabil
determin
nhcinduc
cytotox
cell
plate
treat
nhc
describ
cell
expos
tenpoint
dilut
seri
creat
vitro
efficaci
studi
dmsotreat
cell
serv
cytotox
control
well
without
cell
serv
cytotox
posit
control
hour
cell
viabil
measur
spectramax
molecular
devic
via
celltit
glo
assay
promega
accord
manufactur
protocol
similar
data
obtain
three
independ
experi
cell
adsorb
moi
pfucel
strain
plate
manual
rock
everi
min
redistribut
inoculum
min
viru
inoculum
remov
cell
wash
phosphat
buffer
salin
pb
remov
unbound
viru
medium
contain
nhc
vehicl
control
dmso
ad
back
onto
cell
cell
incub
hour
human
tracheobronchi
epitheli
cell
provid
dr
scott
randel
obtain
airway
specimen
resect
patient
undergo
surgeri
univers
north
carolina
institut
review
boardapprov
protocol
cystic
fibrosi
center
tissu
cultur
core
primari
cell
expand
gener
passag
cell
passag
cell
plate
densiti
cell
per
well
transwellcol
diamet
support
corn
human
airway
epithelium
cultur
hae
gener
provis
airliquid
interfac
week
form
welldifferenti
polar
cultur
resembl
vivo
pseudostratifi
mucociliari
epithelium
hour
prior
infect
apic
surfac
cultur
wash
pb
hour
cultur
move
fresh
air
liquid
interfac
ali
media
immedi
prior
infect
apic
surfac
wash
twice
remov
accumul
mucu
pb
wash
last
min
hae
cultur
move
ali
media
contain
variou
concentr
nhc
rang
indic
experi
final
dmso
upon
remov
second
pb
wash
viral
inoculum
sarsgfp
mersrfp
strain
moi
ad
apic
surfac
hae
cultur
incub
hour
viral
inoculum
remov
apic
surfac
cultur
wash
three
time
pb
incub
hour
post
infect
hpi
hae
cultur
infecti
viru
produc
collect
wash
apic
surfac
cultur
pb
apic
wash
store
analysi
titer
plaqu
assay
previous
describ
qrtpcr
approach
assess
cytotox
total
rna
isol
use
zymo
directzol
rna
miniprep
kit
zymo
research
corp
accord
manufactur
direct
cell
treat
staurosporin
sigmaaldrich
posit
control
firststrand
cdna
gener
use
superscript
iii
revers
transcriptas
life
technolog
quantif
cellular
marker
toxicityapoptosi
realtim
pcr
perform
use
commerci
valid
taqmanbas
primerprob
set
tabl
taqman
univers
pcr
mix
life
technolog
result
normal
describ
mous
lung
store
rnalat
thermofish
process
via
homogen
trizol
invitrogen
total
rna
isol
use
directzol
rna
miniprep
kit
zymo
research
previous
publish
taqman
primer
synthes
integr
dna
technolog
idt
quantifi
mer
genom
rna
target
forward
probe
revers
qrtpcr
perform
use
total
rna
compar
rna
standard
curv
use
taqman
fast
viru
master
mix
thermofish
quant
studio
appli
biosystem
cell
supernat
harvest
trizol
ls
reagent
invitrogen
rna
purifi
follow
phase
separ
chloroform
recommend
manufactur
rna
aqueou
phase
collect
purifi
use
purelink
rna
mini
kit
invitrogen
accord
manufactur
protocol
viral
rna
quantifi
use
onestep
quantit
revers
transcript
pcr
qrtpcr
steponeplu
realtim
pcr
system
appli
biosystem
taqman
fast
viru
master
mix
chemistri
appli
biosystem
n
gene
rna
amplifi
use
forward
revers
primer
probe
design
unit
state
center
diseas
control
prevent
oligonucleotid
produc
idt
cat
copi
number
interpol
standard
curv
produc
dilut
n
gene
rna
briefli
posit
control
plasmid
dna
idt
cat
amplifi
use
forward
revers
primer
result
nucleotid
fragment
contain
promot
pcr
product
purifi
column
promega
vitro
transcrib
use
mmessag
mmachin
transcript
kit
invitrogen
accord
manufactur
protocol
transcrib
rna
purifi
use
rneasi
mini
kit
qiagen
accord
manufactur
protocol
serial
dilut
quantifi
describ
primer
id
ng
design
specif
identifi
remov
rtpcr
mutat
facilit
highli
accur
sequenc
determin
singl
rna
molecul
cdna
creat
barcod
degener
primer
combin
illumina
index
librari
made
use
multiplex
primer
id
librari
prep
approach
miseq
sequenc
investig
presenc
mutat
viral
genom
murin
mrna
design
cdna
primer
target
multipl
region
viral
genom
murin
mrna
block
random
tabl
viral
rna
extract
use
qiaamp
viral
rna
kit
preamplif
titrat
templat
perform
estim
amount
templat
use
use
superscript
iii
make
cdna
multiplex
cdna
primer
base
region
sequenc
use
pilot
sequenc
titrat
determin
merscov
sequenc
multiplex
cdna
reaction
murin
mrna
sequenc
use
mix
primer
bead
purif
amplifi
cdna
mixtur
forward
primer
base
describ
scheme
univers
revers
primer
follow
anoth
round
pcr
incorpor
illumina
sequenc
adaptor
barcod
amplicon
gelpurif
quantif
pool
librari
miseq
base
pairedend
sequenc
tc
pipelin
version
http
githubcomswanstromlabpid
use
process
primer
id
sequenc
data
construct
templat
consensu
sequenc
tcss
repres
individu
input
templat
sequenc
region
pool
demultiplex
rubi
packag
viralseq
version
http
rubygemsorggemsviralseq
use
calcul
mutat
rate
posit
ncbi
sra
access
number
sequenc
data
follow
fig
fig
perform
mous
studi
evalu
vivo
efficaci
nhc
prodrug
first
perform
prophylact
dose
escal
studi
sarsand
merscov
determin
efficaci
dose
per
viru
sarscov
cohort
equival
number
male
femal
week
old
spf
stock
jackson
lab
mice
n
group
administ
vehicl
peg
cremophor
water
mgkg
oral
gavag
hour
prior
intranas
infect
pfu
mouseadapt
sarscov
strain
mice
anaesthet
mixtur
ketaminexylazin
prior
intranas
infect
vehicl
drug
administ
everi
remaind
studi
bodi
weight
pulmonari
function
whole
bodi
plethysmographi
measur
daili
dpi
anim
sacrif
isofluran
overdos
lung
score
lung
hemorrhag
inferior
right
lobe
frozen
viral
titrat
via
plaqu
assay
briefli
vero
cellswel
seed
plate
follow
day
medium
remov
serial
dilut
clarifi
lung
homogen
ad
per
plate
dilut
incub
well
overlaid
dmem
fetal
clone
serum
antibioticantimycot
agaros
two
day
plaqu
enumer
gener
plaqueml
valu
lung
hemorrhag
gross
patholog
phenotyp
readili
observ
nake
eye
driven
degre
viru
replic
color
lung
chang
pink
dark
red
larg
left
lobe
place
buffer
formalin
store
week
histolog
section
analysi
merscov
prophylact
dose
escal
studi
perform
similarli
done
sarscov
recent
develop
mous
model
merscov
human
receptor
perform
vivo
studi
equival
number
week
old
femal
male
mice
second
intranas
infect
mice
pfu
mouseadapt
merscov
strain
third
titer
lung
plaqu
assay
vero
cell
use
plaqu
enumer
dpi
determin
time
therapeut
administr
would
fail
improv
outcom
sarscov
merscov
infect
perform
therapeut
efficaci
studi
mice
initi
treatment
hour
prior
infect
hour
infect
mgkg
provid
complet
protect
diseas
prophylact
sarscov
studi
dose
use
therapeut
efficaci
studi
vehicl
given
via
oral
gavag
twice
daili
follow
initi
treatment
sarscov
merscov
infecti
dose
therapeut
studi
mous
strain
use
prophylact
studi
number
mice
per
group
sarscov
studi
follow
vehicl
n
hour
n
hour
n
hour
n
hour
n
number
mice
per
group
merscov
therapeut
studi
follow
vehicl
n
hour
n
hour
n
hour
n
hour
n
describ
day
mous
bodi
weight
pulmonari
function
quantit
dpi
sarscov
dpi
merscov
anim
human
sacrif
tissu
harvest
analyz
describ
addit
merscov
studi
lung
tissu
harvest
store
rnalat
thermo
fisher
thaw
homogen
trizol
reagent
invitrogen
total
rna
isol
use
directzol
rna
miniprep
kit
zymo
research
total
rna
use
primer
id
qrtpcr
pulmonari
function
monitor
daili
via
wholebodi
plethysmographi
buxco
respiratori
solut
dsi
inc
mice
intend
analysi
randomli
chosen
prior
initi
studi
briefli
acclim
time
plethysmograph
data
paramet
record
everi
min
diminish
histopatholog
featur
associ
lung
injuri
analys
score
perform
board
certifi
veterinari
pathologist
blind
treatment
group
american
thorac
societi
lung
injuri
score
tool
order
help
quantit
histolog
featur
ali
observ
mous
model
increas
translat
human
condit
use
at
score
tool
blind
manner
chose
three
random
diseas
field
lung
tissu
high
power
score
follow
neutrophil
alveolar
space
none
cell
cell
b
neutrophil
interstiti
space
septa
none
cell
cell
c
hyalin
membran
none
one
membran
membran
proteinac
debri
air
space
none
one
instanc
instanc
e
alveolar
septal
thicken
mock
thick
mock
thick
mock
thick
obtain
lung
injuri
score
per
field
score
ae
put
follow
formula
contain
multipli
assign
vari
level
import
phenotyp
diseas
state
score
x
b
x
c
x
x
e
score
three
field
per
mous
averag
obtain
final
score
rang
includ
diffus
alveolar
damag
dad
tool
second
histolog
tool
quantit
lung
injuri
report
schmidt
et
al
dad
patholog
hallmark
ali
three
random
diseas
field
lung
tissu
score
high
power
follow
blind
manner
absenc
cellular
slough
necrosi
uncommon
solitari
cell
slough
necrosi
focifield
multifoc
foci
cellular
slough
necrosi
uncommon
septal
wall
hyalin
multifoc
field
cellular
slough
necrosi
common
andor
promin
hyalin
membran
score
three
field
per
mous
averag
get
final
dad
score
per
mous
coronaviru
rdrp
protein
sequenc
align
phylogenet
tree
gener
use
geneiou
tree
builder
geneiou
prime
version
visual
use
evolview
http
wwwevolgeniusinfoevolview
protein
similar
score
calcul
use
statist
data
analys
perform
graphpad
prism
statist
signific
endpoint
determin
specif
statist
test
gener
metric
multipl
treatment
group
longitudin
data
eg
mous
weight
loss
pulmonari
function
time
twoway
anova
perform
suggest
multipl
comparison
test
advis
prism
compar
data
singl
timepoint
eg
lung
titer
kruskalw
oneway
anova
perform
suggest
multipl
comparison
test
test
pvalu
consid
signific
specif
test
note
figur
legend
three
randomli
chosen
high
power
field
diseas
lung
assess
per
mous
number
mice
score
per
group
vehicl
n
hour
n
hour
n
hour
n
hour
n
asterisk
indic
statist
signific
compar
vehicl
kruskalw
dunn
multipl
comparison
test
panel
box
encompass
percentil
line
median
whisker
repres
rang
hour
hour
compar
vehicl
hour
compar
vehicl
hour
compar
vehicl
